GHRP-2
200–300 mcg · 2-3×/day
Evidence
- Human Studies
- 10
- Animal Studies
- 20
- Clinical Status
- Research
- Confidence
- Low
- Long-Term Safety
- Limited — early pharmaceutical development data only, program not carried to approval
What this score is: a measure of how much research exists and how far along it is (animal-only vs. human trials, research-stage vs. FDA approved) — not how safe, effective, or worth trying a compound is. A low score usually means “early stage” or “understudied,” not “bad.” A high score doesn’t mean “better” for your goals than a lower-scored one.
This is not my personal rating of the compound, not a recommendation, and not medical advice. It’s a general research synthesis for informational purposes only, not a live literature count. See the linked research and talk to a licensed clinician before making decisions based on it.
Mechanism
GHRP-2 is a synthetic hexapeptide ghrelin-receptor agonist that stimulates GH release, with a moderate effect on appetite and a smaller cortisol/prolactin rise than hexarelin but more than ipamorelin. It has undergone some early-phase pharmaceutical development but was not carried to approval.
Common Protocols
- 200–300 mcg subcutaneous, 2-3x daily, commonly stacked with a GHRH analogue like CJC-1295
Side Effects
- Increased hunger
- Injection site reaction
- Mild water retention
- Modest cortisol/prolactin elevation
Interactions
- Combining with other GH secretagogues compounds both effect and risk
Practical Details
- Cost
- $
- Typical Vial Size
- 5 mg
- Storage
- Refrigerate after reconstitution
Research Links
GH secretagogue; moderate appetite stimulation, often paired with CJC-1295